EXTENDED REPORT

Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study

J B Jonas, I Akkoyun, I Kreissig and R F Degenring

Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg, Germany

Correspondence to:
Correspondence to:
Dr J Jonas
Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; Jost.Jonas{at}ma.augen.uni-heidelberg.de

Aim: To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide for treatment of diffuse diabetic macular oedema.

Methods: Prospective, comparative, non-randomised clinical interventional study included 136 patients with diffuse diabetic macular oedema. Patients of the study group (97 eyes) received an intravitreal injection of 20–25 mg of triamcinolone acetonide and no other retinal treatment. Patients of the control group (69 eyes) received focal or panretinal laser treatment if indicated. Mean (standard deviation) follow up was 8.4 (SD 6.0) months (range 1.03–25.2 months).

Results: Visual acuity (VA) increased significantly (p<0.001) in the study group with 66 (68%) eyes gaining in VA by at least two Snellen lines. In the control group, VA did not change significantly during the first 4 months of follow up, and decreased significantly (p<0.001) towards the end of the follow up. Difference in change of best VA was significant (p<0.001) between both groups. Correspondingly, the number of patients with VA improvement of two or more Snellen lines and visual loss of two or more Snellen lines, respectively, was significantly (p<0.001) higher and lower, respectively, in the study group.

Conclusions: Intravitreal triamcinolone acetonide can temporarily increase VA in some patients with diffuse diabetic macular oedema.

Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure; VA, visual acuity

Keywords: triamcinolone acetonide; diabetic retinopathy; diabetic macular oedema; diabetes mellitus; intravitreal medication; intraocular pressure

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Veritti, D., Lanzetta, P., Perissin, L., Bandello, F. (2009). Posterior Juxtascleral Infusion of Modified Triamcinolone Acetonide Formulation for Refractory Diabetic Macular Edema: One-Year Follow-Up. IOVS 50: 2391-2397 [Abstract] [Full Text]  
• Wickremasinghe, S. S., Rogers, S. L., Gillies, M. C., Zhu, M., Wong, T. Y. (2008). Retinal Vascular Caliber Changes after Intravitreal Triamcinolone Treatment for Diabetic Macular Edema. IOVS 49: 4707-4711 [Abstract] [Full Text]  
• Ta, C. N. (2007). Topical Antibiotic Prophylaxis in Intraocular Injections. Arch Ophthalmol 125: 972-974 [Full Text]  
• Lam, D. S C, Chan, C. K M, Mohamed, S., Lai, T. Y Y, Li, K. K W, Li, P. S H, Tsang, C.-W., Chan, W.-M., Shanmugam, M. P (2007). A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br. J. Ophthalmol. 91: 199-203 [Abstract] [Full Text]  
• Albini, T. A., Abd-El-Barr, M. M., Carvounis, P. E., Iyer, M. N., Lakhanpal, R. R., Pennesi, M. E., Chevez-Barrios, P., Wu, S. M., Holz, E. R. (2007). Long-term Retinal Toxicity of Intravitreal Commercially Available Preserved Triamcinolone Acetonide (Kenalog) in Rabbit Eyes. IOVS 48: 390-395 [Abstract] [Full Text]  
• Longo, A (2006). Intravitreal triamcinolone for diffuse diabetic macular oedema.. Br. J. Ophthalmol. 90: 1079-1080 [Full Text]  
• Chan, C K M, Mohamed, S, Shanmugam, M P, Tsang, C-W, Lai, T Y Y, Lam, D S C (2006). Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. Br. J. Ophthalmol. 90: 1137-1141 [Abstract] [Full Text]  
• Zarbin, M. (2006). Should corticosteroids be considered as part of the standard care with photodynamic therapy?. Arch Ophthalmol 124: 563-571 [Full Text]  
• Jonas, J. B., Martus, P., Degenring, R. F., Kreissig, I., Akkoyun, I. (2005). Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema. Arch Ophthalmol 123: 1338-1343 [Abstract] [Full Text]  
• Spandau, U H M, Derse, M, Schmitz-Valckenberg, P, Papoulis, C, Jonas, J B (2005). Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br. J. Ophthalmol. 89: 999-1003 [Abstract] [Full Text]  
• Vernon, S A (2005). Intravitreal triamcinolone therapy for diabetic macular oedema. Br. J. Ophthalmol. 89: 931-933 [Full Text]